MedTrace Logo

Novel Rinse to Treat in Oral Candidiasis in Cancer Patients

NCT00612963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2010-03-08

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy of Iocide oral rinse as a treatment for Oral Candidiasis in any patient including but not limited to patients receiving radiation therapy or who have previously received radiation therapy for head and neck cancer, or patients positive for HIV/AIDS or are transplant patients.

Conditions

  • Candidiasis, Oral
  • Thrush
  • Candidiasis

Interventions

DRUG

Frio Oral Rinse

Prescription Mouth Rinse

Sponsors & Collaborators

  • National Institute of Dental and Craniofacial Research (NIDCR)

    collaborator NIH

  • University of Texas

    collaborator OTHER

  • Biomedical Development Corporation

    lead INDUSTRY

Principal Investigators

  • Spencer W. Redding, DDS · The University of Texas Health Science Center at San Antonio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612963 on ClinicalTrials.gov